Business
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2025 Annual General Meeting will be held on Tuesday, June 24, 2025 at 01:00 p.m. (CEST) at the A
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025","length":83,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2025 Annual General Meeting will be held on Tuesday, June 24, 2025 at 01:00 p.m. (CEST) at the Amsterdam offices of NautaDutilh N.V. The full agenda and all relevant documents are available on the Company's website: https://www.vivoryon.com/2025-annual-general-meeting/.","length":597,"tagName":"p"},{"type":"text","content":"###","length":3,"tagName":"p"},{"type":"text","content":"About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com","length":750,"tagName":"p"},{"type":"text","content":"Vivoryon Forward Looking Statements","length":35,"tagName":"p"},{"type":"text","content":"This press release includes forward-looking statements, including, without limitation, t...